HC Wainwright Begins Coverage on Palisade Bio (NASDAQ:PALI)

Key Points

• HC Wainwright initiated coverage on Palisade Bio with a buy rating and a $7 price target, implying roughly a 246% upside from the prior close.
• Analyst views are mixed but the MarketBeat consensus is a Moderate Buy with a consensus price target of $11; individual targets range widely (e.g., Piper Sandler $25, Stifel $5) and Weiss Ratings remains a sell.
• Palisade is a clinical‑stage biotech whose lead candidate, PDS0108, is an intratumoral TLR9 agonist in Phase 1/2, and several large hedge funds recently initiated multi‑million‑dollar positions, leaving institutional ownership at about 11.8%.

Investment analysts at HC Wainwright started coverage on shares of Palisade Bio (NASDAQ:PALI - Get Free Report) in a note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $7.00 price target on the stock. HC Wainwright's price objective suggests a potential upside of 246.53% from the company's previous close.

Several other equities analysts also recently commented on the stock. Piper Sandler started coverage on shares of Palisade Bio in a research note on Monday, December 29th. They issued an "overweight" rating and a $25.00 price target on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Palisade Bio in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Palisade Bio from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Clear Str upgraded shares of Palisade Bio to a "strong-buy" rating in a research report on Monday, December 29th. Finally, Stifel Nicolaus assumed coverage on Palisade Bio in a research note on Wednesday, February 25th. They issued a "buy" rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $11.00.

Palisade Bio Price Performance

Shares of NASDAQ PALI opened at $2.02 on Thursday. The firm has a market cap of $335.08 million, a price-to-earnings ratio of -0.95 and a beta of 1.53. The stock's fifty day moving average price is $1.77 and its two-hundred day moving average price is $1.73. Palisade Bio has a one year low of $0.53 and a one year high of $2.64.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC bought a new stake in Palisade Bio during the fourth quarter worth $28,318,000. Commodore Capital LP bought a new position in shares of Palisade Bio in the 4th quarter valued at $26,896,000. Janus Henderson Group PLC acquired a new position in shares of Palisade Bio during the 4th quarter worth $24,822,000. RA Capital Management L.P. acquired a new position in shares of Palisade Bio during the 4th quarter worth $16,742,000. Finally, Eversept Partners LP bought a new stake in shares of Palisade Bio during the 4th quarter worth $12,670,000. 11.79% of the stock is owned by institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.